《中国老年代谢综合征药物治疗专家共识(2022)》解读

Interpretation of Expert Consensus on Drug Treatment for Metabolic Syndrome in the Elderly in China(2022)

老年代谢综合征是一组复杂的代谢紊乱症候群,其作为一种共病发病率高,临床表现多样,机制复杂且涉及联合用药,发生药物不良反应的风险高。老年代谢综合征严重损害老年人的生活质量和健康,给我国医疗系统及社会造成沉重的负担。《中国老年代谢综合征药物治疗专家共识(2022)》全面梳理和总结了老年代谢综合征的诊断标准和治疗目标、最新治疗药物及其相互作用,并做出10条推荐意见。该文就共识要点特别是药物治疗方面进行解读,以期为老年代谢综合征药物治疗决策与健康管理提供相关参考。

Metabolic syndrome in the elderly refers to a cluster of metabolic disturbances,characterized by a high comorbidity incidence,varied clinical presentations,intricate mechanisms,and the involvement of polypharmacy,which elevates the risk of adverse drug reactions.Metabolic syndrome severely undermines the quality of life and health among the elderly,placing a significant burden on healthcare system and society in China.Expert Consensus on Drug Treatment for Metabolic Syndrome in the Elderly in China(2022)thoroughly reviewed and summarized the diagnostic criteria and therapeutic objectives for metabolic syndrome in the elderly,provided the latest medications and their interactions,and offered ten recommendation points.This document interprets the key points of the consensus,particularly in terms of pharmacological treatment,and aims to provide relevant references for the decision-making process in the pharmacological management and health care for elderly individuals with metabolic syndrome.